GlassScriptPhysician profile
Kristi Hebert
NPI 1447545058
$3,315.46
in general payments reported to CMS, 2019-2025
31 companies · $539 in 2025
The $539 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $23.90 · 2021: $394 · 2022: $662 · 2023: $696 · 2024: $847 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Travel and Lodging: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.51 |
| Travel and Lodging | $302.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,400.18 | 2019-2025 | Lithovue, General - Erectile Dysfunction, Ams 700 |
| Dendreon Pharmaceuticals LLC | $244.84 | 2022-2024 | Provenge |
| Teleflex LLC | $233.15 | 2022-2024 | Urolift |
| Merck Sharp & Dohme LLC | $161.34 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $108.53 | 2022 | |
| Photocure INC | $97.52 | 2019 | |
| Sumitomo Pharma America, INC. | $88.66 | 2023-2025 | Orgovyx, Gemtesa |
| Novartis Pharmaceuticals Corporation | $79.14 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $77.31 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Ferring Pharmaceuticals INC. | $72.38 | 2024-2025 | Adstiladrin |
| Tolmar, INC. | $69.67 | 2023-2025 | Eligard |
| Procept Biorobotics Corporation | $68.22 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $64.06 | 2021-2023 | Lynparza |
| Astellas Pharma US INC | $57.88 | 2021-2022 | |
| Urovant Sciences INC | $57.22 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $49.04 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.51 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $44.43 | 2023-2025 | Prolaris |
| Allergan, INC. | $40.20 | 2021-2022 | |
| Janssen Biotech, INC. | $28.77 | 2023 | Erleada |
| Progenics Pharmaceuticals, INC. | $27.59 | 2023 | Pylarify |
| Pfizer INC. | $26.83 | 2024 | |
| Pharmaand Gmbh | $25.22 | 2024 | Rubraca |
| Calyxo, INC. | $22.09 | 2025 | Cvac Aspiration System |
| Novo Nordisk INC | $21.38 | 2025 | |
| Endo Pharmaceuticals INC. | $19.98 | 2022 | |
| Immunitybio, INC. | $19.46 | 2024 | |
| Myovant Sciences INC. | $18.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.26 | 2020 | |
| Axonics, INC. | $15.86 | 2024 | Bulkamid |
| Travere Therapeutics, INC. | $13.95 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Hebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.